THURSDAY, Dec. 15, 2022 (HealthDay News) -- An experimental gene therapy that's applied as a skin gel appears to heal wounds caused by a rare and severe genetic skin disease.
Experts called the findings "remarkable," and said they bring hope of a better quality of life to children and young adults living with the condition, called dystrophic epidermolysis bullosa (DEB).
The disease affects about 3 out of every 1 million people. It's caused by a flawed gene that renders the body unable to produce a particular collagen -- a "glue" between the skin layers that is essential to its strength and integrity.
Kids born with DEB are sometimes called "butterfly children" because their skin is so fragile, even an ordinary bump or friction can cause blistering that progresses to painful open wounds.
In the most severe cases, infants have blisters or missing skin at birth, or soon after. Those children typically develop widespread scarring over their bodies and can have eye inflammation that impairs their vision. Blisters and scarring also arise along the lining of the mouth, throat and digestive tract -- which can interfere with eating and cause malnutrition.
As young adults, people with DEB face a high risk of squamous cell carcinoma, a form of skin cancer that is normally highly curable, but in a person with DEB often proves deadly.
There has never been any specific treatment for DEB. Managing it is all about wound care, preventing infections, trying to relieve pain and other "supportive" therapies, said Dr. Peter Marinkovich, the senior researcher on the new study.
"We're helplessly watching blisters and wounds form, without any way to stop them," said Marinkovich, who directs Stanford University's Blistering Disease Clinic.
The new gene therapy, delivered by a skin gel applied directly to wounds, could become the first treatment for the rare disease. Krystal Biotech, the product's developer, has submitted an application for approval to the U.S. Food and Drug Administration, and said the agency granted it "priority review" designation.
The therapy does not correct the genetic flaw causing DEB, or cure the disease.
Instead, the gel contains a modified herpes virus that delivers two functioning copies of the gene, called COL7A1, to patients' skin cells. The cells are then able to produce the missing collagen protein -- with the goal of healing wounds.
In the new trial, published Dec. 15 in the New England Journal of Medicine, Marinkovich and his team found the approach did just that.
The study involved 31 children and adults with DEB. Each patient had one wound treated with the gene therapy gel, and a second, similar wound treated with a placebo (inactive) gel. In all cases, it was applied during weekly bandage changes.
After six months, 67% of wounds treated with the gene therapy were completely closed, versus 22% of those treated with the placebo gel. That included healing of longstanding -- even 10-year-old -- wounds, according to Marinkovich.
Other experts called the trial "pivotal," and said that if the therapy continues to have such benefits over the long term, it could have a "transformational" impact on patients' quality of life.
"This is a devastating disease," said Dr. Aimee Payne, a professor of dermatology at the University of Pennsylvania.
Payne, who wrote an editorial published with the study, said that various high-tech treatments for DEB have been attempted -- including stem cell therapies and skin grafts.
"And now this comes along, and it's a salve that you put on the skin," Payne said. "It almost seems magical."
The notion of topical treatments is new to the gene therapy field, said David Schaffer, a professor of chemical and biomolecular engineering at the University of California, Berkeley.
A limitation of the approach is that it's transient, explained Schaffer, who wrote a separate editorial published with the study. As skin cells naturally die, the functioning COL7A1 gene is lost, too.
So the topical therapy will likely need to be repeated indefinitely. In addition, it does not penetrate the skin, Schaffer said. That means while it can be applied as needed to new wounds, it cannot prevent them.
That said, a gel capable of closing wounds could transform patients' lives, according to Schaffer. And if that healing is ultimately shown to prevent squamous cell carcinoma, he said, "that would be huge."
As for safety, the trial found no serious side effects. A theoretical concern, the experts said, is that the immune system could react against the herpes simplex virus used in the gel, or the newly produced collagen protein.
The herpes virus is genetically modified so that it cannot replicate or spread in the body. But because the virus is naturally adept at evading the immune system, Marinkovich explained, it's a good vehicle for delivering the COL7A1 gene to cells without sparking an immune response.
The skin gel does not address the internal lesions that DEB causes. But, Marinkovich said, it's possible the same gene therapy could be delivered to those areas of the body by other means -- drops for the eyes, an oral "swish" for the mouth, or suppositories for anal lesions.
Among the ongoing research steps, he said, is to treat skin lesions in younger children, as early as 6 months of age, to see if that can prevent extensive skin scarring.
Schaffer pointed to the bigger picture. Gene therapy, he said, has long been "held back" by a lack of good delivery systems. But that's changing. Just last month, Schaffer noted, the first gene therapy for hemophilia B -- delivered by a single IV infusion -- was approved by the FDA.
"Gene therapy is beginning to work," he said.
More information
The nonprofit DEBRA has more on the different forms of epidermolysis bullosa.
SOURCES: M. Peter Marinkovich, MD, associate professor, dermatology, and director, Blistering Disease Clinic, Stanford University School of Medicine; Aimee S. Payne, MD, PhD, professor, dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia; David V. Schaffer, PhD, professor, chemical and biomolecular engineering, bioengineering, molecular and cell biology, University of California, Berkeley; New England Journal of Medicine, Dec. 15, 2022
More here:
Gene Therapy Gel Offers New Hope Against Rare Blistering Disease
- About the Gene Therapy Review - November 8th, 2009 [November 8th, 2009]
- Contribute an Article - November 8th, 2009 [November 8th, 2009]
- EBSCO Publishing Deal - November 8th, 2009 [November 8th, 2009]
- Advertising Opportunities - November 8th, 2009 [November 8th, 2009]
- Instructions for Authors - November 8th, 2009 [November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases - November 8th, 2009 [November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy - November 8th, 2009 [November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy - November 8th, 2009 [November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy - November 8th, 2009 [November 8th, 2009]
- Gene therapy effective in fighting obesity in mice - November 8th, 2009 [November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility - November 8th, 2009 [November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema - December 31st, 2009 [December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb - December 31st, 2009 [December 31st, 2009]
- TNVitamins.com – $10 Off Of $50 order - May 7th, 2011 [May 7th, 2011]
- 15% Off Any PetAlive Order - May 7th, 2011 [May 7th, 2011]
- At PetAlive – $10 off order of $50 or more - May 7th, 2011 [May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order - May 7th, 2011 [May 7th, 2011]
- Native Remedies – Save $5 coupon - May 7th, 2011 [May 7th, 2011]
- Welcome to the Gene Therapy Review - May 15th, 2011 [May 15th, 2011]
- Editorial Board - May 15th, 2011 [May 15th, 2011]
- Gene Therapy Job Board - May 15th, 2011 [May 15th, 2011]
- Corporate Membership - May 22nd, 2011 [May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order - May 29th, 2011 [May 29th, 2011]
- What is Gene Therapy? - June 19th, 2011 [June 19th, 2011]
- Research and Markets: Recent Advances in Cancer Research and Therapy - Increased Research on one of the Major Causes ... - April 25th, 2012 [April 25th, 2012]
- Gene Therapy part 2 - Video - April 30th, 2012 [April 30th, 2012]
- Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- CBS This Morning - Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- Engineering adenoviruses for gene therapy - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy (The General Explains) - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy - Animation - Video - April 30th, 2012 [April 30th, 2012]
- Microbiology Gene Therapy - Video - April 30th, 2012 [April 30th, 2012]
- Gene Therapy in Detail - Video - April 30th, 2012 [April 30th, 2012]
- Breakthrough in Haemophilia treatment - Video - April 30th, 2012 [April 30th, 2012]
- Virology Seminar - Gene Therapy - April 30th, 2012 [April 30th, 2012]
- Gene Therapy Video - Video - April 30th, 2012 [April 30th, 2012]
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 4th, 2012 [May 4th, 2012]
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 4th, 2012 [May 4th, 2012]
- Gene therapy for HIV safe, but effectiveness still unclear - May 4th, 2012 [May 4th, 2012]
- A Step Forward For Gene Therapy To Treat HIV - May 4th, 2012 [May 4th, 2012]
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 4th, 2012 [May 4th, 2012]
- Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy - May 4th, 2012 [May 4th, 2012]
- AIDS gene therapy safe -- is it a "cure"? - May 4th, 2012 [May 4th, 2012]
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 5th, 2012 [May 5th, 2012]
- Lewis speaks on gene therapy at Lexington Community Education event - May 7th, 2012 [May 7th, 2012]
- Penn researchers report a gene-therapy success - May 10th, 2012 [May 10th, 2012]
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012 [May 13th, 2012]
- Gene therapy extends mouse lifespan by 24 pc - May 16th, 2012 [May 16th, 2012]
- Gene therapy dramatically extends mouse lifespan - May 16th, 2012 [May 16th, 2012]
- Gene therapy may extend life: Study - May 16th, 2012 [May 16th, 2012]
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single ... - May 16th, 2012 [May 16th, 2012]
- Gene Therapy Extends Mouse Lifespan - May 16th, 2012 [May 16th, 2012]
- Gene Therapy for Brain Disease - May 17th, 2012 [May 17th, 2012]
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012 [May 17th, 2012]
- FIRST Anti-Aging Gene Therapy (Brainstorm Ep72) - Video - May 23rd, 2012 [May 23rd, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency - May 25th, 2012 [May 25th, 2012]
- RetroSense Therapeutics Completes pre-IND Meeting for RST-001 - May 25th, 2012 [May 25th, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency, study suggests - May 26th, 2012 [May 26th, 2012]
- Alliance for Cancer Gene Therapy celebrates 10 years - May 29th, 2012 [May 29th, 2012]
- Research on gene therapy by Prasad Eye - June 1st, 2012 [June 1st, 2012]
- Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment - June 5th, 2012 [June 5th, 2012]
- Transgenomic Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 ASCO Annual Meeting - June 5th, 2012 [June 5th, 2012]
- Baxter Inks Deal with Chatham - June 6th, 2012 [June 6th, 2012]
- PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic - June 11th, 2012 [June 11th, 2012]
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO - June 15th, 2012 [June 15th, 2012]
- Research and Markets: Gene Therapy - Global Strategic Business Report - 2012 - June 15th, 2012 [June 15th, 2012]
- New York Law Firm’s MesotheliomaHelp.net Site Publishes Interview with Gene Therapy Author - June 17th, 2012 [June 17th, 2012]
- uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy - June 19th, 2012 [June 19th, 2012]
- Anti-cocaine vaccine described in Human Gene Therapy Journal - June 19th, 2012 [June 19th, 2012]
- bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy - June 19th, 2012 [June 19th, 2012]
- Close to a cure: Greater Hartford takes on rare Jewish genetic disease - June 19th, 2012 [June 19th, 2012]
- Gene Therapy Helps Treat Children with Rare Brain Disorder - June 20th, 2012 [June 20th, 2012]
- Gold nanoparticles capable of 'unzipping' DNA - June 21st, 2012 [June 21st, 2012]
- ‘Gene-silencing’ drug can halt and reverse deadly brain disorder - June 21st, 2012 [June 21st, 2012]
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease - June 22nd, 2012 [June 22nd, 2012]
- Gene-silencing method offers possible therapy for Huntington's disease - June 22nd, 2012 [June 22nd, 2012]
- Gene mutations cause massive brain asymmetry - June 24th, 2012 [June 24th, 2012]
- Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ... - June 25th, 2012 [June 25th, 2012]
- Stress Blocks Gene That Guards Brain Against Depression - June 26th, 2012 [June 26th, 2012]
- Targeted gene therapy enhances treatment for Pompe disease - June 26th, 2012 [June 26th, 2012]